Defining the threshold for significant versus insignificant prostate cancer. - Wikidata - awgldk - TriplyDB

Defining the threshold for significant versus insignificant prostate cancer.

Defining the threshold for significant versus insignificant prostate cancer.

http://www.wikidata.org/entity/Q38109810

about

Temporal trends and racial disparities in global prostate cancer prevalence Potential Cross-Talk between Alternative and Classical NF-κB Pathways in Prostate Cancer Tissues as Measured by a Multi-Staining Immunofluorescence Co-Localization Assay Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.The concordance between the volume hotspot and the grade hotspot: a 3-D reconstructive model using the pathology outputs from the PROMIS trial.The prostate cancer susceptibility variant rs2735839 near KLK3 gene is associated with aggressive prostate cancer and can stratify gleason score 7 patients Antitumor effects and molecular mechanisms of figitumumab, a humanized monoclonal antibody to IGF-1 receptor, in esophageal carcinoma.Serum markers in prostate cancer detection Trends in prostate cancer incidence and mortality in Canada during the era of prostate-specific antigen screening.MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery CLINICAL EVALUATION OF AN EPIGENETIC ASSAY TO PREDICT MISSED CANCER IN PROSTATE BIOPSY SPECIMENS.EN2: a novel prostate cancer biomarker.Prognostic prostate tissue biomarkers of potential clinical use.An arranged marriage for precision medicine: hypoxia and genomic assays in localized prostate cancer radiotherapy.Prognostic histopathological and molecular markers on prostate cancer needle-biopsies: a review Current trends and new frontiers in focal therapy for localized prostate cancer.Tumor volume in insignificant prostate cancer: Increasing the threshold is a safe approach to reduce over-treatment.Is There a Future for Chemoprevention of Prostate Cancer?Clinical role of pathological downgrading after radical prostatectomy in patients with biopsy confirmed Gleason score 3 + 4 prostate cancer Predicting Low-Risk Prostate Cancer from Transperineal Saturation Biopsies.Rule-based versus probabilistic selection for active surveillance using three definitions of insignificant prostate cancer.Fibroblast miR-210 overexpression is independently associated with clinical failure in Prostate Cancer - a multicenter (in situ hybridization) study.The prognostic role of immune checkpoint markers programmed cell death protein 1 (PD-1) and programmed death ligand 1 (PD-L1) in a large, multicenter prostate cancer cohort.Epigenetic risk score improves prostate cancer risk assessment.Editorial comment to Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies.Expression of phosphatase of regenerating liver (PRL)-3, is independently associated with biochemical failure, clinical failure and death in prostate cancer.High miR-205 expression in normal epithelium is associated with biochemical failure - an argument for epithelial crosstalk in prostate cancer?Overdiagnosis across medical disciplines: a scoping review.Prognostic utility of biopsy-derived cell cycle progression score in patients with National Comprehensive Cancer Network low-risk prostate cancer undergoing radical prostatectomy: implications for treatment guidance.Upper limit of cancer extent on biopsy defining very low-risk prostate cancer.18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies.The influence of prostate-specific antigen density on positive and negative predictive values of multiparametric magnetic resonance imaging to detect Gleason score 7-10 prostate cancer in a repeat biopsy setting.Stopping screening, when and how?Ultrasensitive electrochemical immunoassay of proteins based on in situ duple amplification of gold nanoparticle biolabel signals.Not all gleason pattern 4 prostate cancers are created equal: A study of latent prostatic carcinomas in a cystoprostatectomy and autopsy series.Accuracy of tumor segmentation from multi-parametric prostate MRI and 18F-choline PET/CT for focal prostate cancer therapy applications.A Novel Flavonoid Composition Targets Androgen Receptor Signaling and Inhibits Prostate Cancer Growth in Preclinical Models.

P2860

Q27006994-B97156DA-4215-4A68-BD76-2EE20A6046D3 Q28546630-F3BA6D13-2D5F-4982-A3FA-E02DE6994678 Q30354652-BB4996DB-EF86-406B-B499-FDDDF6BBF4D7 Q33622330-06DC229B-CA43-48D8-8562-76039AF6C1BE Q34290163-054BD09C-C436-4DC4-BE2E-CD24D402F9E2 Q34431333-2E91289D-8B3A-47CA-A564-93A2B9804D9D Q35042519-F9363468-3007-4FA4-BF5E-985010D9F8EE Q36901009-91F0A751-4CC4-4511-BB7E-D5E24A61115F Q37113174-6F24D167-EDAD-4534-8CF8-E1B348501542 Q37563750-D2F27E3F-B447-4F53-A852-87648ABC48C4 Q38165246-5EF659A4-5596-48A0-87AE-7C4CDD3A9F70 Q38184382-0C821187-95F6-48AF-B2FC-C4FAFE36E27D Q38192714-0B5B2E56-09D2-43D7-95C1-F02DA105A996 Q38253055-8D1E22E6-ED1B-49F0-8414-6181FA288497 Q38436625-1EFEDD98-46A8-44C8-BBC6-F2CA8FC5F20B Q38568583-0C24F726-9597-4A23-86D8-5611F82C87F9 Q38878301-201FC1D8-3B6D-45DF-84E0-12B8CD3894C5 Q39211272-896B3806-188E-420D-A491-28E74EC99970 Q40541815-FD85DE8F-FC8E-477F-8DDC-179FA0F200C0 Q41599088-5A8BE893-3C4A-4CE1-934C-EA4E09B71536 Q41991354-904110EF-DD2D-48EB-9675-D04FFE820CCD Q42265633-91EB5055-3A32-45F0-8C9C-EB9DADD816CA Q43152996-8E6ADEB6-EEF3-4392-ADEA-D06D5A4955F1 Q44001329-751F1702-2FD1-4BFF-97C5-AD983A45E976 Q47123783-23719F00-2FBF-4B05-8EC9-21DC584294CE Q47135859-A3CC1EF7-16B3-41ED-ACC2-0AD1379306D9 Q47237442-A39739AF-371C-4698-B158-2EB75744991A Q47894036-F979B357-D036-412E-A770-7159583C1F00 Q48248936-61B110A7-4404-4CAE-BF68-C7EE451FED93 Q50315275-91C86DC7-A45D-4072-99D1-5A52CBA2A313 Q51595856-91B64930-3F26-410E-A9F0-8CCEEC808C70 Q52624226-A5BDCFE2-E152-4248-9B7D-9C2C5854B94E Q53257680-279A1712-1E48-4267-8F70-84795EF159EA Q53511275-B7398146-B55C-4026-9B0F-3B0FC6917A81 Q55075688-4EB106D6-EDD5-4A95-A96B-F213F854D017 Q55508457-7C2D027D-E63F-4753-A378-78C5D771642A

P2860

Defining the threshold for significant versus insignificant prostate cancer.

http://www.wikidata.org/entity/Q38109810

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Defining the threshold for significant versus insignificant prostate cancer.

@en

type

label

Defining the threshold for significant versus insignificant prostate cancer.

@en

prefLabel

Defining the threshold for significant versus insignificant prostate cancer.

@en

P1433

Q38109810-F26302B7-C0DA-4900-86C0-5832A3D71ED9

P1476

Q38109810-F96BE1E9-8894-4811-8F14-6FD75323DC54

P2093

Q38109810-59474090-719F-4B53-998B-B1501F9E2CE4

Q38109810-FED44DA1-2F95-4E97-B9C0-5D6C92659FED

P2860

Q38109810-009884D1-7C4C-47F2-8B8E-6735DD5C1BF6

Q38109810-0196BFDC-915D-443A-A9DF-523B18FF0D4F

Q38109810-03BE4C7D-5482-4A36-B5D6-6DF0BD289895

Q38109810-0B4B8244-C3C9-4673-932E-E8293EF43080

Q38109810-1483161E-8760-4537-B248-86EBFDD78E5D

Q38109810-17299D9A-E43E-4E2A-A6C7-798D4BC8BF82

Q38109810-200C3B4B-098B-4BE6-935F-99610AC8705B

Q38109810-3071EA25-C968-474C-A1FF-4FCA62F43E40

Q38109810-33C9DD24-6A98-4F11-B1E7-310D214FC57A

Q38109810-360CA464-7EFD-45F7-875B-D21A56CD12A9

P2888

Q38109810-450BA6A0-E27B-42AD-BB57-709856C5DD47

P304

Q38109810-DAD7F09C-9480-4874-92D1-D4B8EE7437A9

P31

Q38109810-9B5B1FE9-F3BB-4F67-951B-D6A9FC528D94

P356

Q38109810-BB2F58E2-AA11-4C46-80E3-14D0E5783F43

P407

Q38109810-381B420B-A7C0-406E-9834-9B6E01C93282

P433

Q38109810-737FB2AE-7818-43C6-A0F2-F36F8016A930

P478

Q38109810-122383DE-51C4-4485-B0F8-617B30C1748E

P50

Q38109810-55110822-24B6-43F6-AECD-239D39E5B942

Q38109810-6C01B9AB-67FB-4C8E-8F14-165D57033D53

P577

Q38109810-F144E3B5-0FF8-4AD1-8393-FFA0EDF9609C

P5875

Q38109810-5E00C8CE-6752-4446-AF1A-65B4896DCEB0

P6179

Q38109810-41BC3D5F-4CFD-4DA7-9E1F-5C6E12A06FFC

P698

Q38109810-0352F103-9075-408E-A652-3DC9D341807B

P356

NRUROL.2013.112

P1433

Nature Reviews Urology

P1476

Defining the threshold for significant versus insignificant prostate cancer

@en

P2093

Monique J Roobol

http://www.w3.org/2001/XMLSchema#string

Theo H Van der Kwast

http://www.w3.org/2001/XMLSchema#string

P2860

Mortality results from a randomized prostate-cancer screening trial

Active surveillance for prostate cancer: progress and promise

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC)

Rethinking screening for breast cancer and prostate cancer

Screening and prostate-cancer mortality in a randomized European study

A critical analysis of the tumor volume threshold for clinically insignificant prostate cancer using a data set of a randomized screening trial.

Cancer surveillance series: interpreting trends in prostate cancer--part I: Evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates.

Complications after prostate biopsy: data from SEER-Medicare.

Comparative studies of prostate cancer in Japan versus the United States. A review.

Overdiagnosis in cancer.

P2888

nrurol.2013.112

P304

473-482

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2013.112

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P50

Theodorus H Van der Kwast

P577

2013-05-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236948575

http://www.w3.org/2001/XMLSchema#string

P6179

1026466985

http://www.w3.org/2001/XMLSchema#string

P698

23712205

http://www.w3.org/2001/XMLSchema#string